Embarking effect of ACE2-angiotensin 1-7/mas receptor axis in benign prostate hyperplasia

Singh, Y; Gupta, G; Sharma, R; Matta, Y; Mishra, A; Pinto, TDJA; Dua, K

Embarking effect of ACE2-angiotensin 1-7/mas receptor axis in benign prostate hyperplasia

Singh, Y Gupta, G Sharma, R Matta, Y Mishra, A Pinto, TDJA Dua, K

Permalink

Publication Type:: Journal Article
Citation:: Critical Reviews in Eukaryotic Gene Expression, 2018, 28 (2), pp. 115 - 124
Issue Date:: 2018-01-01

Closed Access

	Filename	Description	Size
	CRE-21364-Corrected-Proof-05-29-18 (2).pdf	Published Version	683.69 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Singh, Y	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Sharma, R	en_US
dc.contributor.author	Matta, Y	en_US
dc.contributor.author	Mishra, A	en_US
dc.contributor.author	Pinto, TDJA	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.date.issued	2018-01-01	en_US
dc.identifier.citation	Critical Reviews in Eukaryotic Gene Expression, 2018, 28 (2), pp. 115 - 124	en_US
dc.identifier.issn	1045-4403	en_US
dc.identifier.uri	http://hdl.handle.net/10453/134161
dc.description.abstract	© 2018 Begell House, Inc. The proliferative cell process that causes prostate enlargement, obstruction of the bladder outlet, and lower urinary tract symptoms (LUTS) is known as benign prostatic hyperplasia (BPH). The prevalence of BPH worldwide is approximately 10%, 20%, 50%, and 80% for men in their 30s, 40s, 60s, and 70s, respectively. Recent data have revealed that overactivation of the renin angiotensin aldosterone system increases the level of bioactive peptide hormone angiotensin II, which downregulates the ACE2-angiotensin 1-7/Mas receptor axis path and upregulates angiotensin receptor type 1-mediated signaling, which finally leads to a proliferation of cellular elements in the prostate. We have hypothesized the mechanism that reverses the downregulation of the ACE2-angiotensin 1-7/ Mas receptor axis path and the upregulation of angiotensin receptor type 1-mediated signaling. Thus, we posit that ACE2, Ang-(1-7), and the Mas receptor could be novel therapeutic targets for treating BPH/LUTS.	en_US
dc.relation.ispartof	Critical Reviews in Eukaryotic Gene Expression	en_US
dc.relation.isbasedon	10.1615/CritRevEukaryotGeneExpr.2018021364	en_US
dc.subject.classification	Biochemistry & Molecular Biology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Prostatic Hyperplasia	en_US
dc.subject.mesh	Peptidyl-Dipeptidase A	en_US
dc.subject.mesh	Angiotensin II	en_US
dc.subject.mesh	Receptors, G-Protein-Coupled	en_US
dc.subject.mesh	Proto-Oncogene Proteins	en_US
dc.subject.mesh	Signal Transduction	en_US
dc.subject.mesh	Cell Proliferation	en_US
dc.subject.mesh	Gene Expression Regulation, Neoplastic	en_US
dc.subject.mesh	Renin-Angiotensin System	en_US
dc.subject.mesh	Male	en_US
dc.subject.mesh	Molecular Targeted Therapy	en_US
dc.title	Embarking effect of ACE2-angiotensin 1-7/mas receptor axis in benign prostate hyperplasia	en_US
dc.type	Journal Article
utslib.citation.volume	2	en_US
utslib.citation.volume	28	en_US
utslib.for	0604 Genetics	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.issue	2	en_US
pubs.publication-status	Published	en_US
pubs.volume	28	en_US

Abstract:

© 2018 Begell House, Inc. The proliferative cell process that causes prostate enlargement, obstruction of the bladder outlet, and lower urinary tract symptoms (LUTS) is known as benign prostatic hyperplasia (BPH). The prevalence of BPH worldwide is approximately 10%, 20%, 50%, and 80% for men in their 30s, 40s, 60s, and 70s, respectively. Recent data have revealed that overactivation of the renin angiotensin aldosterone system increases the level of bioactive peptide hormone angiotensin II, which downregulates the ACE2-angiotensin 1-7/Mas receptor axis path and upregulates angiotensin receptor type 1-mediated signaling, which finally leads to a proliferation of cellular elements in the prostate. We have hypothesized the mechanism that reverses the downregulation of the ACE2-angiotensin 1-7/ Mas receptor axis path and the upregulation of angiotensin receptor type 1-mediated signaling. Thus, we posit that ACE2, Ang-(1-7), and the Mas receptor could be novel therapeutic targets for treating BPH/LUTS.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/134161